Market Overview

UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward

Share:
Related CRL
Benzinga's Top Upgrades, Downgrades For January 4, 2017
Benzinga's Top Upgrades
John Rogers Comments on Charles River Laboratories Intl (GuruFocus)

JP Morgan raised its rating on Charles River Laboratories (NYSE: CRL) from Neutral to Overweight and increased its price target from $40 to $42.

JP Morgan commented, "Charles River Laboratories (CRL) hosted its annual December guidance call yesterday, reiterating 2012 estimates (albeit with some EPS softness) and introducing 2013 bottom-line estimates 4-5% below consensus in light of the AstraZeneca deal (for which costs will be realized before full revenue benefits). While the news was met with disappointment, with shares -9.4%, we now see risk/reward as favorable heading into 2013 given improving fundamentals (3-5% LC growth projected vs. 1% in 2012, negative growth in 2009-2011), continued cost discipline, and importantly, a 10% free cash flow yield."

Charles River Laboratories closed at $35.65 on Wednesday.

Latest Ratings for CRL

DateFirmActionFromTo
Jan 2017Evercore ISI GroupUpgradesHoldBuy
Dec 2016Goldman SachsUpgradesSellNeutral
Nov 2016BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!